Date:8/7/2012

se of stock options and settlement of restricted stock units, and differences in the dilutive impact of awards granted under either of Express Scripts' or Medco's share-based compensation agreements.  The guidance range assumes full year and second half 2012 adjusted effective tax rates of approximately 39% and 38%, respectively.  Variations in assumed diluted weighted-average shares and tax rate may materially impact the guidance range.  Note: See Appendix for footnotes.
 Appendix  Footnotes ⁽¹⁾Includes home delivery, specialty and other including:  (a) drugs distributed through patient assistance programs (b) drugs we distribute to other PBMs' clients under limited distribution contracts with pharmaceutical manufacturers and (c) FreedomFP claims. ⁽²⁾ Total adjusted claims reflect home delivery claims multiplied by 3, as home delivery claims typically cover a time period 3 times longer than retail claims. ⁽³⁾ Amortization of legacy Express Scripts intangible assets include amounts in both revenues and selling, general and administrative expense. Revenue amortization is related to the customer contract with WellPoint which consummated upon closing of the NextRx acquisition in 2009.  Under U.S. GAAP standards, amortization of intangibles that arise in connection with consideration given to a customer by a vendor is characterized as a reduction of revenues.  Intangible amortization of $28.5 million ($16.5 million and $18.0 million net of tax in 2012 and 2011, respectively) is included as a reduction to revenue for the three months ended June 30, 2012 and 2011.
Intangible amortization of $57.0 million ($34.5 million and $36.1 million net of tax in 2012 and 2011, respectively) is included as a reduction to revenue for the six months ended June 30, 2012 and 2011.
In addition, intangible amortization of $10.2 million ($5.9 million and $6.4 million net of tax i
'/>"/>

SOURCE Express Scripts Copyright©2012 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12
Related medicine technology :

1. Sigma-Aldrich Accelerates Analytical Research and Extends Benefits of Fused-Core Particle Technology to All HPLC Users with the Launch of New Ascentis Express 5 Micron Particle by Supelco
2. Express Scripts Holding Company Announces Second Quarter 2012 Earnings Conference Call
3. Selexis Lubris Partnership Advances Difficult-to-Express Protein Towards Clinic
4. Generex Announces OncUView.tv Interviews Featuring the Antigen Express AE37 Breast Cancer Vaccine at ASCO 2012
5. Law Office of Brodsky & Smith, LLC Announces Investigation of SRI Surgical Express, Inc.
6. Generex Augments Antigen Express Scientific Advisory Board
7. Generex Announces New Members of Antigen Express Scientific Advisory Board for the AE37 Breast Cancer Vaccine
8. Ceregene Parkinsons Disease Study Demonstrates Long-term Neurturin Expression and Enhanced Dopamine Activity 4 Years Following Delivery of CERE-120 (AAV2-neurturin)
9. Generex Announces Presentations of Antigen Express AE37 Breast Cancer Vaccine Data at ASCO 2012
10. Express Scripts to Present at Bank of America Merrill Lynch Conference
11. Developers: Deadline Approaching for Allscripts Million Hearts CDS Challenge